Out of 3 analysts covering Rewalk Robotics (NASDAQ:RWLK), 2 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Rewalk Robotics was the topic in 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Below is a list of Rewalk Robotics Ltd (NASDAQ:RWLK) latest ratings and price target changes.
18/12/2015 Broker: Barclays Capital Rating: Equal Weight Old Target: $9.00 New Target: $11.00 Target Up
06/11/2015 Broker: Barclays Capital Rating: Equal Weight Old Target: $10.00 New Target: $9.00 Target Down
The stock decreased 2.70% or $0.26 on April 7, hitting $9.37. About 42,141 shares traded hands. Rewalk Robotics Ltd (NASDAQ:RWLK) has risen 16.98% since September 1, 2015 and is uptrending. It has outperformed by 12.19% the S&P500.
Rewalk Robotics Ltd is an Israel-based medical device company. The company has a market cap of $120.77 million. The Firm is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It currently has negative earnings. The Firm has developed and is continuing to commercialize ReWalk, an exoskeleton that uses its patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Rewalk Robotics Ltd - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.